Skip to content

Psilocybin research published in 2023

Page 9 of 19: studies 161 to 180 of 375, newest first. Back to the psilocybin overview

Studies

Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study

Nature Medicine July 24, 2023 Samantha Shao, Tessa Gruen, Alexandra Babakanian et al. 150 citations

Abstract Anorexia nervosa (AN) is a deadly illness with no proven treatments to reverse core symptoms and no medications approved by the US Food and Drug Administration. Novel treatments are urgently needed to improve clinical outcomes. In this open-label feasibility study, 10 adult female participants (mean body mass index 19.7 kg m − 2 ; s.d. 3.7) who met Diagnostic and Statistical Manual of...

Assessing the risk of symptom worsening in psilocybin-assisted therapy for depression: A systematic review and individual participant data meta-analysis

Psychiatry Research July 23, 2023 Otto Simonsson, Per Carlbring, Robin Carhart-Harris et al. 24 citations

We conducted a meta-analysis using individual participant data from three, two-dose psilocybin trials for depression (N = 102) with the aim of assessing the risk of symptom worsening. Clinically significant symptom worsening occurred for a minority of participants in the psilocybin and escitalopram conditions (∼10%) and for a majority of participants in the waitlist condition (63.6%). Using...

DOI: 10.1016/j.psychres.2023.115349 (opens in new tab) Meta-analysis Psilocybin therapy Clinical depression treatment Psychedelic medicine +2

Recent developments involving psychedelics

World drug report July 20, 2023 4 citations

The therapeutic use of psychedelic substances such as LSD and psilocybin has been researched by psychologists and psychiatrists for a range of psychiatric disorders, including substance use disorders. Most of the early research around the therapeutic use of psychedelics was based on case studies or clinical trials that did not meet the contemporary standards of randomized clinical trials, e.g....

DOI: 10.18356/9789210028233c023 (opens in new tab) Psilocybin Mental health Depression economics Clinical trial +3

Distinctive Molecular and Metabolic Profiles of Chemically Synthesized Psilocybin and Psychedelic Mushroom Extract

Research Square July 20, 2023 Orr Shahar, Alexander Botvinnik, Amit Shwartz et al. 3 citations preprint

Abstract Psilocybin, a naturally occurring, tryptamine alkaloid prodrug, is currently being investigated for the treatment of a range of psychiatric disorders. Preclinical reports suggest that the biological effects of psilocybin-containing mushroom extract or “full spectrum” (psychedelic) mushroom extract (PME), may differ from those of chemically synthesized psilocybin (PSIL). We compared the...

Psilocybin Therapy for Major Depressive Disorder: A Systematic Review

Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal July 19, 2023 Kaden Venugopal 1 citation

Introduction: Major depressive disorder (MDD) is a prevalent and complex mood disorder. Its psychotherapies often involve delayed treatment-response times, while its pharmacotherapies can cause unwanted side effects. In recent years, there has been a resurgence in psychedelic research with a specific interest in the potential of psilocybin for treating MDD. Therefore, this systematic review was...

DOI: 10.26685/urncst.489 (opens in new tab) Psilocybin Peer review Medical education Library science +1

Personality Change in a Trial of Psilocybin Therapy vs Escitalopram Treatment for Depression – CORRIGENDUM

Psychological Medicine July 19, 2023 Brandon Weiss, Induni Ginige, Lu Shannon et al. 1 citation

An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the 'Save PDF' action button.

Psilocybin-assisted psychotherapy for cancer-related anxiety and depression

International Journal of Gynecological Cancer July 18, 2023 Dan Yaniv, L. Ramondetta, L. Cohen et al.

Women with gynecologic cancers face various physical and psychological challenges throughout their treatment journey. Late stages associated with poor prognosis, along with chronic side effects of treatment, often leave women with existential uncertainty stemming from unpredictable disease trajectory and continuous fear of death. Recently, a patient in her late 30s (JN) with endstage ovarian...

Pharmacognostic, Forensic and Pharmaceutical, Organizational and Legal, Clinical and Pharmacological Multidisciplinary Study with an Assessment of Peculiarities of Circulation (Use) of Smoking Mixtures of Spices and Entheogens of Amanita Muscaria Mushroom

SSP Modern Pharmacy and Medicine July 18, 2023 Вікторія Шаповалова, Alina Osyntseva, Валерій Шаповалов et al. 18 citations

A multidisciplinary pharmacognostic, forensic and pharmaceutical, organizational and legal, clinical and pharmacological, forensic and medical, toxicological, chemical evaluation of the irrational use of spices in smoking mixtures from the group of entheogens was carried out. An expert assessment of spices – plants and mushrooms containing psychoactive substances with hallucinogenic effects....

DOI: 10.53933/sspmpm.v3i3.105 (opens in new tab) Psilocybin Amanita Traditional medicine Mushroom poisoning +3

Administration effects of four psilocybin mushroom extracts on serotonin levels and endothelial nitric oxide synthase activity levels in vivo and in vitro after one hour

Research Square July 18, 2023 Sanah Malomile Nkadimeng, L. Hay, Christiaan Ml Steinmann et al. 1 citation preprint

Abstract Background Psilocybin-containing mushrooms induce antidepressant and momentary increase in blood pressure (BP) with potential risk to users with cardiovascular diseases. Irregularities in nitric oxide (NO) levels play a key role in endothelial dysfunctions leading to increases in BP. Mushrooms species show large variation in potency which may potentially induce different outcomes and...

Imprinting: expanding the extra-pharmacological model of psychedelic drug action to incorporate delayed influences of sets and settings

Frontiers in Human Neuroscience July 18, 2023 Nicolas Garel, Julien Thibault Lévesque, Dasha A. Sandra et al. 29 citations

Background Psychedelic drug experiences are shaped by current-moment contextual factors, commonly categorized as internal (set) and external (setting). Potential influences of past environments, however, have received little attention. Aims To investigate how previous environmental stimuli shaped the experiences of patients receiving ketamine for treatment-resistant depression (TRD), and...

Comparing Neural Correlates of Consciousness: From Psychedelics to Hypnosis and Meditation

Biological Psychiatry: Cognitive Neuroscience and Neuroimaging July 17, 2023 Flora Moujaes, Nathalie M. Rieser, Christophe Phillips et al. 19 citations

BACKGROUND: Pharmacological and nonpharmacological methods of inducing altered states of consciousness (ASCs) are becoming increasingly relevant in the treatment of psychiatric disorders. While comparisons between them are often drawn, to date no study has directly compared their neural correlates. METHODS: To address this knowledge gap, we directly compared 2 pharmacological methods...

Increased low-frequency brain responses to music after psilocybin therapy for depression.

Journal of Affective Disorders July 15, 2023 Matthew B. Wall, Cynthia Lam, Natalie Ertl et al. 36 citations

Psychedelic-assisted psychotherapy with psilocybin is an emerging therapy with great promise for depression, and modern psychedelic therapy (PT) methods incorporate music as a key element. Music is an effective emotional/hedonic stimulus that could also be useful in assessing changes in emotional responsiveness following PT. Brain responses to music were assessed before and after PT using...

Translation and Initial Psychometric Evaluation of Spanish Versions of Three Psychedelic Acute Effects Measures: Mystical, Challenging, and Insight Experiences

Journal of Psychoactive Drugs July 14, 2023 Christopher Timmermann, Aki Nikolaidis, Alan K. Davis et al. 4 citations

This study translated and tested the psychometric properties of acute psychedelic effects measures among Spanish-speaking people. The Psychological Insight Questionnaire (PIQ), Challenging Experiences Questionnaire (CEQ), and Mystical Experiences Questionnaire (MEQ) were translated before being incorporated into a web-based survey. We recruited native Spanish-speakers (N = 442; Mage = 30.8, SD...

DOI: 10.1080/02791072.2023.2232379 (opens in new tab) Psilocybin Confirmatory factor analysis Clinical psychology Prosocial behavior +4

Outcomes of usage of psychedelics by people reporting an eating disorder in clinical and non-clinical settings: a scoping review

Advances in Mental Health July 13, 2023 Jorge Valdiviezo‐oña, Lizbeth Toscano-Molina, Juan Fernando Chávez et al. 4 citations

Objective To map the studies reporting the use of psychedelics in clinical and non-clinical settings by people reporting an eating disorder (ED) and their outcomes.Method To be included, peer-reviewed articles had to be written in English or Spanish and had to address the usage of psychedelics by people reporting an ED. Searches were conducted on PubMed, Scopus, and Web of Science. Data on key...

Australia’s approval of MDMA and psilocybin for PTSD and depression is premature, say critics

British medical journal July 11, 2023 B. Nogrady 18 citations

The TGA attached conditions to their use: namely, that onlypsychiatristswhoare trainedandauthorised to prescribe MDMA and psilocybin can do so, that a human research ethics committeemust approve each patient case, and that the treatments must be used in conjunction with psychotherapy.1 An officer of the TGA and the ethics committee must also satisfy themselves that “a suitably robust treatment...

Leveraging psychedelic therapies for binge eating disorder

Open Access Government July 10, 2023 Jim Gilligan

Leveraging psychedelic therapies for binge eating disorder Here Tryp Therapeutics examine the viability of using psychedelic therapies for Binge Eating Disorder and the potential results that using psychedelic-assisted psychotherapy could have on different eating disorders. Tryp Therapeutics is a clinical-stage biotechnology company dedicated to the development of exclusive and innovative...

[Psychedelic Experiences: Phenomenology, Therapeutic Potentials and Explanatory Models].

Vertex Revista Argentina de Psiquiatría July 10, 2023 Tamara Chernoff, Bruno Kliger, Dante Hernán Venturini

Traditional psychedelics, such as LSD, psilocybin, or DMT, are psychoactive compounds that exert their effects mainly through agonism over serotonergic receptors. In appropriate doses and contexts, they produce profound changes in the subjective experience, configuring altered states of consciousness that, upon reaching a critical point, involve the appearance of phenomena of mystical,...

Ethopharmacological evaluation of antidepressant-like effect of serotonergic psychedelics in C57BL/6J male mice

Research Square July 7, 2023 Rika Takaba, Daisuke Ibi, Keisuke Yoshida et al. 4 citations preprint

Abstract Serotonergic psychedelics such as psilocybin, lysergic acid diethylamide, and DOI exert a hallucinatory effect through serotonin 5-HT 2A receptor (5-HT2A) activation. Recent studies have revealed that serotonergic psychedelics have therapeutic potential for neuropsychiatric disorders, including major depressive and anxiety-related disorders. However, the involvement of 5-HT2A in...

Psychoactive substances in psychotherapy - A vision for the future? – A systematic review on Psilocybin

July 6, 2023 Jenny Tetem, Tamara Fischmann, Tim Julian Möller preprint

This work is a literature review on the use of psilocybin in psychotherapeutic treatment of mental illnesses. The review answers the question of what opportunities and risks are associated with the use of the psychoactive substance psilocybin. Peer-reviewed studies between 2017 and 2022 were included. Nine studies were found regarding the following indications: tobacco addiction, anxiety and...